



Join more than 2,000 providers in the urology-specific data registry!

How the AQUA Registry can support your practice:

MERIT-BASED INCENTIVE PAYMENT SYSTEM (MIPS) REPORTING TO CMS

As a Qualified Clinical Data Registry (QCDR), the AQUA Registry is your one-stop shop to streamline the MIPS reporting process to CMS:

- Report on both urology-relevant and general CMS-approved Quality Payment Program measures.
- Identify a set of measures with the highest performance scores
- Offer attestation modules to satisfy the requirements in the Promoting Interoperability (PI) and Improvement Activities (IA) categories.

QUALITY IMPROVEMENT

The AQUA Registry dashboard identifies low-performing clinical areas in need of quality improvement. By examining contributing factors to these areas, an action plan for correction can be implemented and evaluated throughout the year.

CLINICAL TRIALS OPPORTUNITIES

Leverage AQUA Registry data and Verana Trial Connect technology to connect patients to clinical trials based on inclusion/exclusion criteria.



NATIONAL BENCHMARKING

Standard performance reports through the AQUA Registry dashboard allow you to:

- Review performance scores against peers at the physician level
- Identify low-performance areas for improvement

UROLOGY-SPECIFIC MEASURES

AUA-generated performance measures benchmark compliance with clinical practice guidelines for treating patients with urologic diseases. By selecting urology-specific measures, providers can report on in areas that are relevant to the urology specialty.

Prostate cancer, bladder cancer, benign prostatic hyperplasia (BPH) and urinary stones, are some of the conditions covered by the AUA measures.

PROFESSIONAL DEVELOPMENT

By utilizing the AQUA Registry dashboard and reporting tools, eligible urologists can receive Practice Assessment Protocol (PAP) credit for the Life Long Learning Program (formerly MOC) made available through the American Board of Urology (ABU).



Recent Publications Using AQUA Data

Velez C, Bowman M, Shapiro K, Mbassa R, Fang R, Brucker B, van Kuiken M (April 2023), Choice of First Medication Prescribed for Overactive Bladder Changes with Time: Trend from AUA AQUA Registry, Journal of Urology.

Cooperberg MR, Meeks W, Fang R, Gaylis FD, Catalona WJ, Makarov DV (March 2023), *Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US, JAMA Network Open.*

Dani H, Meeks W, Weiss C, Fang R, Cohen AJ (January 2023), Patterns of Surgical Management of Male Stress Urinary Incontinence: Data from the AUA Quality (AQUA) Registry, Urology Practice.

Cooperberg MR, Mbassa R, Walker D, Meeks W, Lockefeer A, Jiang B, Li T, Johnston K, Fang R (January 2023), Insights from the AQUA Registry: A Retrospective Study of Anticholinergic Polypharmacy in the United States, Therapeutic Advances in Urology.

Brendel P, Torres A, Arah OA (January 2023), Simultaneous Adjustment of Uncontrolled Confounding, Selection Bias, and Misclassification in Multiple-Bias Modelling, International Journal of Epidemiology.

Jericevic D, Shapiro K, Bowman M, Vélez CA, Mbassa R, Fang R, Van Kuiken M, Brucker BM. (January 2024), Who Progresses to Third-Line Therapies for Overactive Bladder? Trends From the AQUA Registry, Urology Practice.

Bowman M, Vélez CA, Jericevic D, Shapiro K, Mbassa R, Fang R, Brucker BM, Van Kuiken M. (December 2023), Factors Influencing Medication Selection for Management of Overactive Bladder: Trends and Insights From AUA Quality Registry, Urology.